The Annals of thoracic surgery
-
In spite of modern cardiac surgical techniques, severe cardiogenic shock not responding to pharmacologic therapy and intraaortic balloon pumping develops in about 0.2% to 1.2% of patients undergoing cardiac operations. ⋯ The results justify the use of Thoratec assist device in patients with severe preoperative cardiogenic shock.
-
Recent changes in health care financing have raised the specter of operation-specific, volume credentialing for cardiac surgeons. To meet this challenge, the leadership of The Society of Thoracic Surgeons formed an Ad Hoc Committee to study the question of the relationship of case volume to outcome. One product of the committee's work in this analysis of data from The Society of Thoracic Surgery National Cardiac Database. ⋯ Although the data are practice-group-specific only, there was no clinically relevant correlation of volume to outcome except at extremely low annual volume (less than 100 cases per year). Variability of outcome was significant in lower volume practices (less than 600 cases/year) and varied little at more than 600 cases per year. There were no differences in expected mortality regardless of the size of the practice.
-
Postcardiotomy cardiogenic shock remains a challenging situation. Many devices can be used although none of them directly unload the left ventricle except for the Hemopump. We report our clinical experience with the Hemopump 31 or sternotomy Hemopump. ⋯ Factors showing adverse effect are biventricular failure, vasoconstrictor requirement, and delayed insertion. We believe the Hemopump is a more efficient device than the intraaortic balloon pump, and that early use after onset of heart failure achieves better results.
-
Centrifugal pumps have been employed most commonly for postcardiotomy mechanical support after intraaortic balloon pumping has failed. Despite their effectiveness in some patients, morbidity remains high. ⋯ Increasing clinical experience with centrifugal mechanical assist appears to result in a clinically relevant decrease in morbidity.
-
The University of Alabama at Birmingham experience with investigational ventricular assist devices (VADs) used as a bridge to transplantation has increased over the past several years; it now includes 27 VAD implantations with 13 VAD runs lasting for extended periods (ie, > 30 days). A review of complications experienced by patients during extended VAD runs is warranted before the further development and testing of chronically implanted mechanical circulatory support devices. ⋯ Infection during VAD support pending cardiac transplantation is an important cause of morbidity and mortality in patients maintained for longer than 30 days by circulatory assist. Infectious complications will probably be a prominent component of the risk associated with the use of chronically implanted mechanical circulatory assist devices and will likely have an important effect on the quality of life experienced by these patients.